Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Orosomucoid influences the response to antidepressants in major depressive disorder.

Harley J, Roberts R, Joyce P, Mulder R, Luty S, Frampton C, Kennedy M.

J Psychopharmacol. 2010 Apr;24(4):531-5. doi: 10.1177/0269881109105101. Epub 2009 Apr 24.

PMID:
19395425
2.

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.

Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA.

Hum Psychopharmacol. 2004 Jan;19(1):17-23.

PMID:
14716707
3.

A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender.

Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM.

Acta Psychiatr Scand. 2003 Jul;108(1):20-3.

PMID:
12807373
4.

Childhood neglect and abuse as predictors of antidepressant response in adult depression.

Johnstone JM, Luty SE, Carter JD, Mulder RT, Frampton CM, Joyce PR.

Depress Anxiety. 2009;26(8):711-7. doi: 10.1002/da.20590.

PMID:
19544315
5.

Tryptophan and tyrosine availability and response to antidepressant treatment in major depression.

Porter RJ, Mulder RT, Joyce PR, Luty SE.

J Affect Disord. 2005 Jun;86(2-3):129-34.

PMID:
15935231
6.

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.

Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.

J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22.

PMID:
19027961
7.

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.

Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH.

Am J Psychiatry. 2006 Jul;163(7):1161-72.

PMID:
16816220
8.

alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.

Adeoye OM, Ferrell RE, Kirshner MA, Mulsant BH, Seligman K, Begley AE, Reynolds CF 3rd, Pollock BG.

J Geriatr Psychiatry Neurol. 2003 Dec;16(4):235-9.

PMID:
14653433
9.

The relationship of personality disorders to treatment outcome in depressed outpatients.

Mulder RT, Joyce PR, Luty SE.

J Clin Psychiatry. 2003 Mar;64(3):259-64.

PMID:
12716266
10.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
11.

Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.

Pérez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F; Grup de Recerca en Trastorns Afectius.

J Clin Psychopharmacol. 2001 Feb;21(1):36-45.

PMID:
11199945
12.

Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response.

Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ, Hou SJ, Yen FC.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):637-41. doi: 10.1016/j.pnpbp.2009.02.020. Epub 2009 Mar 9.

PMID:
19272410
13.

Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.

Tsai SJ, Hong CJ, Liou YJ, Chen TJ, Chen ML, Hou SJ, Yen FC, Yu YW.

Psychiatry Res. 2009 Sep 30;169(2):113-7. doi: 10.1016/j.psychres.2008.06.028. Epub 2009 Aug 22.

PMID:
19700204
14.

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

Hong CJ, Chen TJ, Yu YW, Tsai SJ.

Pharmacogenomics J. 2006 Jan-Feb;6(1):27-33.

PMID:
16302021
15.

Nortriptyline for treatment-resistant depression.

Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M.

J Clin Psychiatry. 2003 Jan;64(1):35-9.

PMID:
12590621
16.
17.
18.

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.

Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.

Arch Gen Psychiatry. 2004 Dec;61(12):1235-44.

PMID:
15583115
19.

[Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: results of the ORACLE survey].

Spadone C, Sylvestre M, Chiarelli P, Richard-Berthe C.

Encephale. 2005 Nov-Dec;31(6 Pt 1):698-704. French.

PMID:
16462689
20.

Relationships among measures of treatment outcome in depressed patients.

Mulder RT, Joyce PR, Frampton C.

J Affect Disord. 2003 Sep;76(1-3):127-35.

PMID:
12943942

Supplemental Content

Support Center